Erasca, Inc. Form 10-Q Summary
Business context and reporting period
Erasca is a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers. Its disclosed pipeline included 11 programs, with three clinical-stage programs, one preclinical program and seven discovery-stage programs. The filing covers the three months ended March 31, 2022, with comparative results for the three months ended March 31, 2021. The company had no approved products and no product revenue.
Key financial metrics
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $27.4 million | $12.2 million |
| In-process R&D expense | $2.0 million | $3.7 million |
| General and administrative expense | $7.1 million | $3.7 million |
| Total operating expenses | $36.5 million | $19.6 million |
| Net loss | $36.5 million | $18.0 million |
| Basic and diluted loss per share | $0.31 | $0.81 |
| Net cash used in operating activities | $25.8 million | $15.7 million |
Net loss margin and operating margin are not meaningful because the company generated no revenue. Stock-based compensation was $4.4 million, compared with $0.8 million in the prior-year quarter.
At March 31, 2022, cash and cash equivalents were $333.3 million, short-term marketable securities were $59.2 million, long-term marketable securities were $29.2 million, and total cash, cash equivalents and marketable securities were approximately $421.8 million. Total assets were $475.5 million, total liabilities were $50.8 million and stockholders’ equity was $424.7 million. The filing does not report outstanding debt; liabilities primarily included operating lease obligations and current operating liabilities.
Material changes versus the prior comparable period
- Research and development expense increased $15.2 million, or approximately 124%, primarily due to higher clinical, preclinical and discovery activity, increased personnel costs, stock-based compensation, outsourced services and facility costs.
- Total operating expenses increased $16.9 million, or approximately 86%.
- Net loss increased $18.4 million, reflecting higher operating expenses and the absence of the $1.6 million gain from the change in fair value of a preferred stock purchase right liability recorded in Q1 2021.
- Cash used in operating activities increased $10.1 million to $25.8 million.
- Financing cash inflow declined to $0.5 million from $120.5 million because Q1 2021 included $119.4 million of net proceeds from convertible preferred stock issuance; Q1 2022 financing activity primarily reflected stock-option exercises.
- In-process R&D expense in Q1 2022 reflected a $2.0 million development milestone payment under the Katmai license agreement. Q1 2021 included $3.7 million related primarily to the Emerge Life Sciences asset acquisition.
Guidance, outlook, risks and unusual items
- Management expects operating expenses and losses to increase substantially as clinical trials, preclinical programs, manufacturing activities, personnel and public-company costs expand.
- Based on current operating plans, management expects cash, cash equivalents and marketable securities at March 31, 2022 to fund operations into the second half of 2024. The financial statements separately state that available resources should fund operations for at least one year from issuance of the statements.
- The company expects to report Phase 1b monotherapy data for ERAS-007 and Phase 1 monotherapy data for ERAS-601 in the second half of 2022.
- The company expected to file an IND for ERAS-3490, its CNS-penetrant KRAS G12C inhibitor candidate, in the second half of 2022. It also expected four product candidates to be in the clinic in 2023 and an additional IND filing every 12–18 months through 2026.
- Key development risks include clinical-trial execution, patient enrollment, safety and efficacy outcomes, regulatory approval, manufacturing and supply-chain dependence, intellectual-property protection, and the uncertain timing and cost of development programs.
- The company has no manufacturing facilities and relies on third parties for manufacturing, packaging, storage and distribution. It also relies on third-party products in combination trials, including collaboration arrangements with Pfizer and Eli Lilly.
- COVID-19 had not materially disrupted operations through the filing date, but management noted potential risks to supply chains, clinical enrollment, trial execution and development costs.
- Future contractual exposure includes potential development, regulatory and commercial milestones under license agreements, including up to $90.0 million under the Asana arrangement, as well as royalty and sublicensing obligations under several agreements.
- Long-term facility commitments are significant. The 2020 lease includes approximately $51.6 million of aggregate monthly payments beginning in April 2023, and the 2021 lease includes approximately $34.4 million of aggregate monthly payments beginning in November 2022, each subject to escalation and other terms.
- No material legal proceedings, off-balance-sheet arrangements or material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Verify the company’s cash runway against actual quarterly cash burn, clinical-trial spending and planned milestone payments.
- Track enrollment, safety, pharmacokinetic and proof-of-concept data for ERAS-007, ERAS-601 and ERAS-801.
- Assess whether the planned IND and clinical-stage timelines remain achievable and adequately funded.
- Review potential dilution from 17.3 million outstanding stock options, 16.9 million awards available for future grant and future equity financing needs.
- Evaluate lease commitments, tenant-improvement obligations and the timing of rent commencement relative to projected cash use.
- Monitor third-party manufacturing capacity, combination-drug supply arrangements and the potential effects of COVID-19 or other supply-chain disruptions.
- Confirm the terms, probability and timing of future license milestones, royalties and other contingent obligations.